Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002029680 | SCV002299670 | uncertain significance | not provided | 2022-08-22 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 515 of the SLC6A19 protein (p.Asn515Lys). This variant is present in population databases (rs372599057, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SLC6A19-related conditions. ClinVar contains an entry for this variant (Variation ID: 1514953). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002492372 | SCV002779071 | uncertain significance | Hyperglycinuria; Neutral 1 amino acid transport defect; Iminoglycinuria | 2022-04-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002548811 | SCV003565878 | uncertain significance | Inborn genetic diseases | 2022-08-08 | criteria provided, single submitter | clinical testing | The c.1545T>A (p.N515K) alteration is located in exon 11 (coding exon 11) of the SLC6A19 gene. This alteration results from a T to A substitution at nucleotide position 1545, causing the asparagine (N) at amino acid position 515 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |